Rapid Micro Biosystems (RPID) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 Apr, 2026Executive summary
The 2026 Annual Meeting will be held virtually on May 21, 2026, allowing electronic voting and Q&A participation for Class A stockholders of record as of March 31, 2026.
Proxy materials are distributed primarily online to reduce environmental impact and costs, with options for print upon request.
Only Class A stockholders may vote; Class B stockholders are not entitled to vote at the meeting.
Voting matters and shareholder proposals
Stockholders will vote on electing Richard Kollender as a Class II Director (term expiring 2029) and ratifying PricewaterhouseCoopers LLP as the independent auditor for 2026.
The Board recommends voting FOR both proposals.
Shareholder proposals for the 2027 meeting must be submitted by December 9, 2026, for inclusion in proxy materials.
Board of directors and corporate governance
The Board consists of seven members divided into three staggered classes, with annual elections for expiring terms.
Six directors are independent under Nasdaq rules; the CEO is not independent.
Committees include Audit, Compensation, and Nominating and Corporate Governance, each with defined charters and independent membership.
The Board separates the roles of Chair and CEO, with the Chair currently independent.
Director candidates are evaluated for diversity, experience, and integrity; stockholders may recommend candidates.
Latest events from Rapid Micro Biosystems
- Record revenue and recurring growth driven by automation, global adoption, and margin expansion.RPID
44th Annual J.P. Morgan Healthcare Conference13 Apr 2026 - Achieved record growth and margin expansion by automating pharma microbial quality control.RPID
Corporate presentation8 Apr 2026 - Director election and auditor ratification are up for vote at the 2026 annual meeting.RPID
Proxy filing8 Apr 2026 - 2026 targets strong revenue growth, margin gains, and broad market expansion through automation.RPID
2026 KeyBanc Capital Markets Healthcare Forum17 Mar 2026 - Record revenue growth and major system orders drive strong 2026 outlook and margin expansion.RPID
Q4 202512 Mar 2026 - Record revenue and automation drive global growth and innovation in microbial quality control.RPID
TD Cowen 46th Annual Health Care Conference6 Mar 2026 - Record Q2 revenue, margin gains, and cost actions set path to positive cash flow by 2027.RPID
Q2 20242 Feb 2026 - Growth Direct platform drives record growth, operational efficiency, and expanding pharma adoption.RPID
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Record Q3 revenue, positive margin, and strong system placements support 2027 cash flow goal.RPID
Q3 202417 Jan 2026